Sacituzumab Govitecan

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 696 publications

Efficacy and safety of sacituzumab govitecan in hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.

Efficacy and safety of sacituzumab govitecan in hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: June 19, 2026

Rapid and Efficient Antibody-Drug Conjugate Design Using Mechanistic Bottom-Up Modeling from In Vitro to Human.

Rapid and Efficient Antibody-Drug Conjugate Design Using Mechanistic Bottom-Up Modeling from In Vitro to Human.

Journal: Bioconjugate chemistry

Published: June 19, 2026

Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells.

Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 17, 2026

Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.

Antibody-Drug Conjugates for Locally Advanced and Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.

Journal: JAMA network open

Published: June 01, 2026

Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.

Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 31, 2026

Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions.

Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions.

Journal: Future oncology (London, England)

Published: May 27, 2026

ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer.

ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer.

Journal: Expert opinion on biological therapy

Published: May 20, 2026

Evolving Treatment Paradigms in Hormone Receptor-Positive, Human Epidermal Growth Factor 2-Negative Metastatic Breast Cancer.

Evolving Treatment Paradigms in Hormone Receptor-Positive, Human Epidermal Growth Factor 2-Negative Metastatic Breast Cancer.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 19, 2026

Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study.

Re: Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-invasive Bladder Cancer (SURE-02): A Single-arm, Phase 2 Study.

Journal: European urology

Published: May 05, 2026

Sacituzumab Govitecan as an Effective Strategy for Sensitizing Chemoresistant HNSCC Cells to Senolytic Intervention.

Sacituzumab Govitecan as an Effective Strategy for Sensitizing Chemoresistant HNSCC Cells to Senolytic Intervention.

Journal: bioRxiv : the preprint server for biology

Published: April 27, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

Journal: International journal of clinical oncology

Published: April 09, 2026

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Journal: Current oncology reports

Published: April 09, 2026

Showing 1-12 of 696

Last Updated: 06/30/2026